Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 1/20 | 0.50 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.50 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.50 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.50 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1914984 | 0.84 | BPTF (0.52) | CHRNB2CHRNB4CHRNA3CHRNA7CHRNA4 | |
| SCHEMBL14704709 | 0.84 | BPTF (0.52) | CHRNB2CHRNB4CHRNA3CHRNA7CHRNA4 | |
| SCHEMBL28762510 | 0.84 | BPTF (0.52) | CHRNB2CHRNB4CHRNA3CHRNA7CHRNA4 | |
| SCHEMBL1711174 | 0.84 | CYP2C9 (0.45) | CHRNB2CHRNB4CHRNA3CHRNA7CHRNA4 | |
| Hydrochloric Acid SCHEMBL23091800 | 0.83 | BPTF (0.50) | CHRNB2CHRNB4CHRNA3CHRNA7CHRNA4 | |
| SCHEMBL4776900 | 0.80 | CYP2C9 (0.47) | CYP2C9POLBL3MBTL1ALDH1A1RAB9A | |
| SCHEMBL12207380 | 0.78 | CYP2C9 (0.57) | CYP2C9POLBL3MBTL1ALDH1A1RAB9A | |
| SCHEMBL9635205 | 0.76 | TSHR (0.45) | CYP2C9POLBL3MBTL1ALDH1A1KMT2A | |
| SCHEMBL19051706 | 0.74 | POLB (0.70) | CYP2C9POLBL3MBTL1ALDH1A1KMT2A | |
| SCHEMBL17304912 | 0.74 | CYP2C9 (0.52) | CYP2C9POLBL3MBTL1ALDH1A1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0665228-B1 | Pharmaceutical compositions containing 3-phenylsulfonyl-3,7-diazabicyclo 3,3,1 nonanes | SOLVAY PHARM GMBH (DE) | 1999-07-14 | — | — | EP | claimed |
| US-5576327-A | Treatment of heart rhythym disorders by administration of 3-phenylsulfonyl-3, 7-diazabicyclo[3.3.1]nonane compounds | KALI-CHEMIE PHARMA GMBH (DE) | 1996-11-19 | — | — | US | claimed |
| JP-7267954-A | — | — | None | — | — | JP | disclosed |
| JP-2005232179-A | ANTIARRYTHMIC AGENT CONTAINING 3-PHENYLSULFONYL-3,7-DIAZABICYCLO[3,3,1]NONANE COMPOUND | SOLVAY PHARMACEUT GMBH | 2005-09-02 | — | — | JP | disclosed |
| JP-2005232179-A | ANTIARRYTHMIC AGENT CONTAINING 3-PHENYLSULFONYL-3,7-DIAZABICYCLO[3,3,1]NONANE COMPOUND | SOLVAY PHARMACEUT GMBH | 2005-09-02 | — | — | JP | disclosed |
| US-6602880-B2 | 3-phenyl-3,7-diazabicyclo[3.3.1] nonane compounds, process for preparing them, pharmaceutical compositions containing them and use thereof to inhibit cardiac arrhythmia | SOLVAY PHARMACEUTICALS GMBH (DE) | 2003-08-05 | — | — | US | disclosed |
| US-20030109541-A1 | 3-Phenyl-3,7-diazabicyclo[3.3.1] nonane compounds, process for preparing them, pharmaceutical compositions containing them and use thereof to inhibit cardiac arrhythmia | SOLVAY PHARMACEUTICALS GMBH (DE) | 2003-06-12 | — | — | US | disclosed |
| US-5635511-A | ACID ADDITION SALT DERIVATIVES; ANTIARRHYTHMIA AGENTS; ACTIVE SUPPRESSION OF EXTRASYSTOLES, VENTRICULAR FLUTTERS AND FIBRILLATIONS | KALI-CHEMIE PHARMA GMBH (DE) | 1997-06-03 | — | — | US | disclosed |
| US-5635511-A | ACID ADDITION SALT DERIVATIVES; ANTIARRHYTHMIA AGENTS; ACTIVE SUPPRESSION OF EXTRASYSTOLES, VENTRICULAR FLUTTERS AND FIBRILLATIONS | KALI-CHEMIE PHARMA GMBH (DE) | 1997-06-03 | — | — | US | disclosed |
| US-5635511-A | ACID ADDITION SALT DERIVATIVES; ANTIARRHYTHMIA AGENTS; ACTIVE SUPPRESSION OF EXTRASYSTOLES, VENTRICULAR FLUTTERS AND FIBRILLATIONS | KALI-CHEMIE PHARMA GMBH (DE) | 1997-06-03 | — | — | US | disclosed |
| US-5576327-A | Treatment of heart rhythym disorders by administration of 3-phenylsulfonyl-3, 7-diazabicyclo[3.3.1]nonane compounds | KALI-CHEMIE PHARMA GMBH (DE) | 1996-11-19 | — | — | US | disclosed |
| US-5576327-A | Treatment of heart rhythym disorders by administration of 3-phenylsulfonyl-3, 7-diazabicyclo[3.3.1]nonane compounds | KALI-CHEMIE PHARMA GMBH (DE) | 1996-11-19 | — | — | US | disclosed |
| US-5576327-A | Treatment of heart rhythym disorders by administration of 3-phenylsulfonyl-3, 7-diazabicyclo[3.3.1]nonane compounds | KALI-CHEMIE PHARMA GMBH (DE) | 1996-11-19 | — | — | US | disclosed |
| JP-H07267954-A | NOVEL 3-PHENYLSULFONYL-3,7-DIAZABICYCLO(3,3,1)NONANE COMPOUND, PRODUCTION THEREOF AND ANTIARRYTHMIC AGENT | KALI CHEM PHARMA GMBH | 1995-10-17 | — | — | JP | disclosed |
| EP-0665228-A1 | Pharmaceutical compositions containing 3-phenylsulfonyl-3,7-diazabicyclo 3,3,1 nonanes | Kali-Chemie Pharma GmbH (DE) | 1995-08-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030109541-A1 | 3-Phenyl-3,7-diazabicyclo[3.3.1] nonane compounds, process for preparing them, pharmaceutical compositions containing them and use thereof to inhibit cardiac arrhythmia | SCN1B, KCNH1, SCN2B | CHRNB2 1089/4885CHRNB4 1354/4885CHRNA3 770/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.